Politico April 18, 2024
By Ben Leonard and Chelsea Cirruzzo

Driving The Day

‘ALL OR NOTHING’ — As employers across the country grapple with how to cover costly weight-loss drugs like Ozempic and Wegovy, pushback from drugmakers and the pharmaceutical middlemen that negotiate drug costs is making the decision even harder, POLITICO’s Kelly Hooper reports.

North Carolina’s state health plan voted to end coverage of weight-loss drugs Wegovy and Saxenda in January, citing concerns that costs could balloon to more than $1 billion over the next six years.

That means the 750,000 public employees enrolled in the plan must pay out of pocket for access to the drugs. And the state, the drugmakers and the state’s pharmacy benefit manager, CVS Caremark, blame each other.

“The contracts between the manufacturers and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Employer, Govt Agencies, Patient / Consumer, Pharma / Biotech, Provider, Regulations, States
How digital health companies are capitalizing on the GLP-1 boom
Journalists Zero In on Bird Flu and Weight Loss Drugs
GLP-1 Agonists in Adolescents and Young Adults; Benefits of Cancer Drug Trials
Chasing the alchemy of trial diversity with a mix of culture change and practical mechanics
Ozempic Drug Semaglutide Could Protect Kidneys, Study Finds

Share This Article